{"nctId":"NCT02576860","briefTitle":"Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle","startDateStruct":{"date":"2015-10"},"conditions":["Rosacea"],"count":263,"armGroups":[{"label":"Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: CLS001 (Omiganan)"]},{"label":"Vehicle Gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]}],"interventions":[{"name":"CLS001 (Omiganan)","otherNames":[]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy, male and non-pregnant female subjects, 18 years of age or older.\n2. A diagnosis of papulopustular rosacea with â‰¥30 inflammatory facial lesions at Baseline. Subjects must have no more than 2 nodular lesions, at Baseline.\n3. Subjects with the presence of telangiectasia at Baseline.\n4. Subjects with an erythema score of at least 2 on the Investigator Assessment of Erythema scale at Baseline.\n5. Subjects with severe rosacea on the Investigators Global Assessment scale at Baseline.\n\nExclusion Criteria:\n\n1. Subjects with steroid rosacea or subtype 3 (phymatous rosacea).\n2. Subjects with nodular rosacea.\n3. Standard exclusion criteria.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy Absolute Change in Inflammatory Lesion Count","description":"Absolute change in inflammatory lesion count from baseline to Week 12.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.8","spread":"2.29"},{"groupId":"OG001","value":"-20.9","spread":"2.36"}]}]}]},{"type":"PRIMARY","title":"Efficacy IGA: 2 Grade Reduction","description":"Proportion of Subjects Who Achieved 2 Grade IGA Reduction at Week 12. IGA scores are from 0 to 5 (Clear, Almost Clear, Mild, Moderate and Severe).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"25.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy The Absolute Change in Inflammatory Lesions","description":"The absolute change in inflammatory lesions from baseline to Week 9.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.6","spread":"2.23"},{"groupId":"OG001","value":"-20.9","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Efficacy The Absolute Change in Inflammatory Lesions","description":"The absolute change in inflammatory lesions from baseline to Week 6.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":"1.96"},{"groupId":"OG001","value":"-19.8","spread":"2.06"}]}]}]},{"type":"SECONDARY","title":"Efficacy IGA: 2 Point Reduction","description":"Proportion of Subjects Who Achieved 2 Grade IGA Reduction at Week 9. IGA scores are from 0 to 5 (Clear, Almost Clear, Mild, Moderate and Severe).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null},{"groupId":"OG001","value":"21.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy IGA: 2 Point Reduction","description":"Proportion of Subjects Who Achieved 2 Grade IGA Reduction at Week 6. IGA scores are from 0 to 5 (Clear, Almost Clear, Mild, Moderate and Severe).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null},{"groupId":"OG001","value":"15.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Safety Adverse Events","description":"Subjects with 1 or more treatment-related Treatment-Emergent Adverse Events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":136},"commonTop":["Viral upper respiratory tract infection","Headache","Application site pain","Application site erythema","Application site pruritus"]}}}